Immunic presents data from phase 2 caldose-1 trial of vidofludimus calcium in ulcerative colitis at the united european gastroenterology week 2023

New york , oct. 16, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 caldose-1 trial of vidofludimus calcium (imu-838) in an oral presentation at the united european gastroenterology week (uegw) 2023, taking place october 14-17 in copenhagen. geert r. d'haens, m.d.
IMUX Ratings Summary
IMUX Quant Ranking